Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMWA10
|
|||
| Drug Name |
Batoclimab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Myasthenia gravis [ICD-11: 8C6Y] | Phase 3 | [1] | |
| Company |
Immunovant New York, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neonatal Fc receptor (FCGRT) | Target Info | Antagonist | [2] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05403541) A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG). U.S.National Institutes of Health. | |||
| REF 2 | Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur J Neurol. 2023 Jan;30(1):195-203. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.